TN2009000079A1 - Use of 2-6 (3-amino-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile - Google Patents

Use of 2-6 (3-amino-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile

Info

Publication number: TN2009000079A1
Authority: TN; Tunisia
Prior art keywords: benzonitrile; dioxo; pyrimidin; piperidin; dihydro
Prior art date: 2007-03-13

Application number

TN2009000079A

Other languages

English (en)

Inventor

Ronald J Christopher

Atsushi Ogawa

Paul Ocovington

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-13

Filing date

2009-03-10

Publication date

2010-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40028130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000079(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-10 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2010-08-19 Publication of TN2009000079A1 publication Critical patent/TN2009000079A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Virology (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Hematology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Emergency Medicine (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

TN2009000079A 2007-03-13 2009-03-10 Use of 2-6 (3-amino-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile TN2009000079A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89462807P	2007-03-13	2007-03-13
PCT/US2007/078177 WO2008033851A2 (fr)	2006-09-13	2007-09-11	Administration d'inhibiteurs de la dipeptidyl peptidase

Publications (1)

Publication Number	Publication Date
TN2009000079A1 true TN2009000079A1 (en)	2010-08-19

Family

ID=40028130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2009000079A TN2009000079A1 (en)	2007-03-13	2009-03-10	Use of 2-6 (3-amino-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile

Country Status (34)

Country	Link
US (2)	US20080287476A1 (fr)
EP (1)	EP2073810B1 (fr)
JP (2)	JP5791228B2 (fr)
KR (4)	KR20090088854A (fr)
CN (2)	CN103211819A (fr)
AR (2)	AR062760A1 (fr)
AT (1)	ATE522216T1 (fr)
AU (1)	AU2007296556B2 (fr)
BR (1)	BRPI0716971A2 (fr)
CA (1)	CA2663279C (fr)
CL (1)	CL2007002649A1 (fr)
CO (1)	CO6160321A2 (fr)
CY (1)	CY1112292T1 (fr)
DK (1)	DK2073810T3 (fr)
EA (1)	EA017799B1 (fr)
EC (1)	ECSP099250A (fr)
ES (1)	ES2370873T3 (fr)
GE (1)	GEP20125701B (fr)
HR (1)	HRP20110800T1 (fr)
IL (1)	IL197502A (fr)
JO (1)	JO2755B1 (fr)
MA (1)	MA30725B1 (fr)
MX (1)	MX2009002772A (fr)
MY (1)	MY145447A (fr)
NO (1)	NO342004B1 (fr)
NZ (1)	NZ575521A (fr)
PE (1)	PE20081150A1 (fr)
PL (1)	PL2073810T3 (fr)
PT (1)	PT2073810E (fr)
RS (1)	RS51965B (fr)
SI (1)	SI2073810T1 (fr)
TN (1)	TN2009000079A1 (fr)
TW (1)	TWI434838B (fr)
WO (1)	WO2008033851A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200838536A (en) *	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CL2008000727A1 (es) *	2007-03-13	2008-10-17	Takeda Pharmaceutical	Granulo compuesto por 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluorobenzonitrilo o una de sus sales y un aditivo que no comprende celulosa microcristalina; preparacion solida; comprimido y procedimi
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
ES2764251T3 (es)	2008-08-15	2020-06-02	Boehringer Ingelheim Int	Inhibidores de DPP-4 para uso en el tratamiento de curación de heridas en pacientes diabéticos
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (zh)	2009-01-29	2015-01-01	Boehringer Ingelheim Int	小兒科病人糖尿病之治療
WO2010092163A2 (fr)	2009-02-13	2010-08-19	Boehringer Ingelheim International Gmbh	Médicaments antidiabétiques
CA2769177A1 (fr)	2009-07-28	2011-02-03	Takeda Pharmaceutical Company Limited	Comprime
BR112012012641A2 (pt)	2009-11-27	2020-08-11	Boehringer Ingelheim International Gmbh	TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
WO2011079778A1 (fr)	2009-12-30	2011-07-07	China Shanghai Fochon Pharmaceutical Co Ltd	Dérivés de 3-(3-aminopipéridin-1-yl)-5-oxo-1,2,4-triazine à titre d'inhibiteurs de dipeptidyl peptidase iv (dpp-iv)
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US20130109703A1 (en)	2010-03-18	2013-05-02	Boehringer Ingelheim International Gmbh	Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
NZ602921A (en)	2010-05-05	2016-01-29	Boehringer Ingelheim Int	Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
WO2011157827A1 (fr)	2010-06-18	2011-12-22	Sanofi	Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
KR20190050871A (ko)	2010-06-24	2019-05-13	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012118945A2 (fr)	2011-03-03	2012-09-07	Merck Sharp & Dohme Corp.	Hétérocycles bicycliques fondus, utilisés comme inhibiteurs de la dipeptidylpeptidase-4
WO2013037390A1 (fr)	2011-09-12	2013-03-21	Sanofi	Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr)	2011-09-27	2015-10-21	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013106868A1 (fr) *	2012-01-13	2013-07-18	Chromatin, Inc.	Modification génétique de plantes avec des gènes du métabolisme du farnésène à vitesse limitée
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
CN104519874B (zh)	2012-06-05	2018-08-03	武田药品工业株式会社	固体制剂
US11087354B2 (en) *	2012-08-17	2021-08-10	Genentech, Inc.	Combination therapies
IN2015DN03795A (fr)	2012-10-24	2015-10-02	Inserm Inst Nat De La Santé Et De La Rech Médicale
BR112017007720B1 (pt) *	2014-10-17	2023-01-17	Hyundai Pharm Co., Ltd.	Composição contendo derivado de ácido 3-(4-(benzilóxi)fenil)hex-4-inoico e outro princípio ativo para prevenir ou tratar doenças metabólicas
MX381234B (es) *	2015-01-30	2025-03-12	Taiho Pharmaceutical Co Ltd	Agente preventivo y/o terapéutico de enfermedad inmune.
EP3273981B1 (fr)	2015-03-24	2020-04-29	INSERM - Institut National de la Santé et de la Recherche Médicale	Procédé et composition pharmaceutique pour une utilisation dans le traitement du diabète
CN106608853B (zh) *	2015-10-27	2019-10-25	北京福元医药股份有限公司	二肽基肽酶ⅳ抑制剂的制备方法

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2004A (en) *		1841-03-12		Improvement in the manner of constructing and propelling steam-vessels
GB1053063A (fr) *	1963-05-18
DE1670912C3 (de) *	1967-08-18	1981-06-11	Bayer Ag, 5090 Leverkusen	Herbizide Mittel auf Basis von 1,2,4-Triazin-5-onen
US3960949A (en) *	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
US3823135A (en) *	1972-12-26	1974-07-09	Shell Oil Co	Pyrimidone herbicides
US4494978A (en) *	1976-12-30	1985-01-22	Chevron Research Company	Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides
US5614492A (en) *	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3856378T2 (de) *	1987-09-04	2000-05-11	Beecham Group P.L.C., Brentford	Substituierte Thiazolidindionderivate
US4935493A (en) *	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en) *	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
US5366862A (en) *	1990-02-14	1994-11-22	Receptor Laboratories, Inc.	Method for generating and screening useful peptides
US5387512A (en) *	1991-06-07	1995-02-07	Merck & Co. Inc.	Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation
US5229468A (en) *	1992-02-13	1993-07-20	Hercules Incorporated	Polymer precursor for silicon carbide/aluminum nitride ceramics
IL106998A0 (en) *	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
IL111785A0 (en) *	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
DE69521500T2 (de) *	1994-03-08	2001-12-13	Otsuka Pharmaceutical Factory, Inc.	Phosphorsäurediester-derivate
US5580979A (en) *	1994-03-15	1996-12-03	Trustees Of Tufts University	Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
WO1995034538A2 (fr) *	1994-06-10	1995-12-21	Universitaire Instelling Antwerpen	Purification de proteases serines, et leurs inhibiteurs synthetiques
US5601986A (en) *	1994-07-14	1997-02-11	Amgen Inc.	Assays and devices for the detection of extrahepatic biliary atresia
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en) *	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
US6325989B1 (en) *	1995-06-01	2001-12-04	Dana-Farber Cancer Institute, Inc.	Form of dipeptidylpeptidase IV (CD26) found in human serum
US6265551B1 (en) *	1995-06-01	2001-07-24	Dana-Farber Cancer Institute, Inc.	Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof
DE122010000020I1 (de) *	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
US20020006899A1 (en) *	1998-10-06	2002-01-17	Pospisilik Andrew J.	Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5885997A (en) *	1996-07-01	1999-03-23	Dr. Reddy's Research Foundation	Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
CZ298812B6 (cs) *	1996-07-01	2008-02-13	Dr. Reddy's Laboratories Limited	Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
US7235627B2 (en) *	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6006753A (en) *	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
GB9702701D0 (en) *	1997-02-01	1997-04-02	Univ Newcastle Ventures Ltd	Quinazolinone compounds
US20030060434A1 (en) *	1997-02-18	2003-03-27	Loretta Nielsen	Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6100234A (en) *	1997-05-07	2000-08-08	Tufts University	Treatment of HIV
EP0897012A1 (fr) *	1997-07-05	1999-02-17	Societe Des Produits Nestle S.A.	Clonage de la prolyl-dipeptidyl-peptidase d'Aspergillus oryzae
US6235493B1 (en) *	1997-08-06	2001-05-22	The Regents Of The University Of California	Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
IL135068A (en) *	1997-09-29	2004-03-28	Point Therapeutics Inc	Stimulation of hematopoietic cells in vitro
US6485955B1 (en) *	1997-10-06	2002-11-26	The Trustees Of Tufts University	Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease
US6342611B1 (en) *	1997-10-10	2002-01-29	Cytovia, Inc.	Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
WO1999025719A1 (fr) *	1997-11-18	1999-05-27	Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai	Substance physiologiquement active, la sulphostine, procede de fabrication et utilisation
FR2771004B1 (fr) *	1997-11-19	2000-02-18	Inst Curie	Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
US6380357B2 (en) *	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
BR9813608B1 (pt) *	1997-12-16	2011-11-01		célula hospedeira de bacillus transgênica, e, processo para produzir um polipeptìdeo tendo atividade aminopeptidase.
US20020061839A1 (en) *	1998-03-09	2002-05-23	Scharpe Simon Lodewijk	Serine peptidase modulators
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
JP2002517401A (ja) *	1998-06-05	2002-06-18	ポイントセラピューティクス，インコーポレイテッド	環状ボロプロリン化合物
DE19828113A1 (de) *	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) *	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
CO5150173A1 (es) *	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB9906715D0 (en) *	1999-03-23	1999-05-19	Ferring Bv	Compositions for promoting growth
US6548529B1 (en) *	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
EP1180121B9 (fr) *	1999-05-17	2004-09-08	Conjuchem, Inc.	Peptides insulinotropes a longue duree d'action
DE19926233C1 (de) *	1999-06-10	2000-10-19	Probiodrug Ges Fuer Arzneim	Verfahren zur Herstellung von Thiazolidin
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
DE19940130A1 (de) *	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US6559188B1 (en) *	1999-09-17	2003-05-06	Novartis Ag	Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6414002B1 (en) *	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6251391B1 (en) *	1999-10-01	2001-06-26	Klaire Laboratories, Inc.	Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons
US6261794B1 (en) *	1999-10-14	2001-07-17	Saint Louis University	Methods for identifying inhibitors of methionine aminopeptidases
ATE292464T1 (de) *	1999-11-09	2005-04-15	Alcon Inc	Heteroatomunterbrochene analoge von15- hydroxyeicosatetraensäure und verfahren zu deren verwendung
GB9928330D0 (en) *	1999-11-30	2000-01-26	Ferring Bv	Novel antidiabetic agents
WO2001041779A2 (fr) *	1999-12-08	2001-06-14	1149336 Ontario Inc.	Traitement relatif a la chimiotherapie
US6380398B2 (en) *	2000-01-04	2002-04-30	Novo Nordisk A/S	Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ES2275654T5 (es) *	2000-01-21	2012-06-07	Novartis Ag	Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
BR0107837A (pt) *	2000-01-27	2003-01-14	Lilly Co Eli	Processo para solubilização de compostos peptìdeo 1 semelhantes a glucagon
US6569901B2 (en) *	2000-01-28	2003-05-27	Novo Nordisk A/S	Alkynyl-substituted propionic acid derivatives, their preparation and use
US6395767B2 (en) *	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6555519B2 (en) *	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
BR0109553A (pt) *	2000-03-31	2003-06-03	Probiodrug Ag	Método para o melhoramento de sinalização de ilhota em diabetes melito e para sua prevenção
US6573096B1 (en) *	2000-04-01	2003-06-03	The Research Foundation At State University Of New York	Compositions and methods for inhibition of cancer invasion and angiogenesis
US6545170B2 (en) *	2000-04-13	2003-04-08	Pharmacia Corporation	2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
EP2223922B1 (fr) *	2000-04-25	2016-03-02	ICOS Corporation	Inhibiteurs delta de phosphatidyl-inositol 3-kinase humaine
GB0010183D0 (en) *	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
US6783757B2 (en) *	2000-06-01	2004-08-31	Kirkman Group, Inc.	Composition and method for increasing exorphin catabolism to treat autism
US6432969B1 (en) *	2000-06-13	2002-08-13	Novartis Ag	N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2002002560A2 (fr) *	2000-07-04	2002-01-10	Novo Nordisk A/S	Composes heterocycliques inhibiteurs de l'enzyme dpp-iv
JP2002042960A (ja) *	2000-07-25	2002-02-08	Yazaki Corp	コネクタ支持機構
WO2002010139A1 (fr) *	2000-08-01	2002-02-07	Pharmacia Corporation	Derives d'acide hexahydro-7-1h-azepine-2-yl-hexanoique comme inhibiteurs d'oxyde nitrique synthase inductible
ES2311532T3 (es) *	2000-08-04	2009-02-16	Warner-Lambert Company Llc	2-(4-pirdil)amino-6-dialcoxifenil-pirido(2.3-d)pirimidin-7-onas.
US20020037829A1 (en) *	2000-08-23	2002-03-28	Aronson Peter S.	Use of DPPIV inhibitors as diuretic and anti-hypertensive agents
PE20020453A1 (es) *	2000-09-27	2002-06-06	Merck & Co Inc	Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos
BR0115055A (pt) *	2000-10-30	2003-12-30	Ortho Mcneil Pharm Inc	Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos
AU2002246568A1 (en) *	2000-10-31	2002-08-06	Vanderbilt University	Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor- and vasopeptidase inhibitor-associated angioedema
AU2002225954A1 (en) *	2000-11-08	2002-05-21	The University Of Georgia Research Foundation, Inc.	Dipeptidylpeptidases and methods of use
US20030055052A1 (en) *	2000-11-10	2003-03-20	Stefan Peters	FAP-activated anti-tumor compounds
US20020155565A1 (en) *	2000-11-10	2002-10-24	Pilar Garin-Chesa	FAP-activated anti-tumor compounds
US20030203946A1 (en) *	2000-11-17	2003-10-30	Carsten Behrens	Glucagon antagonists/inverse agonists
EP1343763A1 (fr) *	2000-11-20	2003-09-17	Bristol-Myers Squibb Company	Derives de pyridones utilises en tant qu'inhibiteurs ap2
WO2002083143A1 (fr) *	2000-12-11	2002-10-24	Tularik Inc.	Antagonistes de cxcr3
SK288003B6 (sk) *	2001-02-24	2012-10-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthin derivatives, method for the preparation thereof, pharmaceutical composition containing thereof and their use
US6337069B1 (en) *	2001-02-28	2002-01-08	B.M.R.A. Corporation B.V.	Method of treating rhinitis or sinusitis by intranasally administering a peptidase
FR2822826B1 (fr) *	2001-03-28	2003-05-09	Servier Lab	Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE10115921A1 (de) *	2001-03-30	2002-10-02	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von 4,6-Diaminopyrimido[5,4-d]pyrimidinen
US6890905B2 (en) *	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention
PE20021080A1 (es) *	2001-04-12	2003-02-12	Boehringer Ingelheim Int	Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
US6573287B2 (en) *	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) *	2001-05-15	2005-05-06	Servier Lab	Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7105556B2 (en) *	2001-05-30	2006-09-12	Bristol-Myers Squibb Company	Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US6794379B2 (en) *	2001-06-06	2004-09-21	Tularik Inc.	CXCR3 antagonists
US20030130199A1 (en) *	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US20030135023A1 (en) *	2001-06-27	2003-07-17	Hans-Ulrich Demuth	Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
US7368421B2 (en) *	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US6869947B2 (en) *	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
UA74912C2 (en) *	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP1285922A1 (fr) *	2001-08-13	2003-02-26	Warner-Lambert Company	1-alkyl ou 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones comme inhibiteurs de phosphodiestérase
US6844316B2 (en) *	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
US6673829B2 (en) *	2001-09-14	2004-01-06	Novo Nordisk A/S	Aminoazetidine,-pyrrolidine and -piperidine derivatives
US20030186963A1 (en) *	2001-09-14	2003-10-02	Dorwald Florencio Zaragoza	Substituted piperidines
EP1463727A2 (fr) *	2001-09-19	2004-10-06	Novo Nordisk A/S	Composes heterocycliques constituant des inhibiteurs de l'enzyme dpp-iv
US7019010B2 (en) *	2001-09-27	2006-03-28	Novertis Ag	Combinations
JP4394442B2 (ja) *	2001-10-01	2010-01-06	ブリストル−マイヤーズスクイブカンパニー	抗炎症剤として有用なスピロ−ヒダントイン化合物
US7064135B2 (en) *	2001-10-12	2006-06-20	Novo Nordisk Inc.	Substituted piperidines
US6861440B2 (en) *	2001-10-26	2005-03-01	Hoffmann-La Roche Inc.	DPP IV inhibitors
EP1442028A4 (fr) *	2001-11-06	2009-11-04	Bristol Myers Squibb Co	Derives d'acides substitues en tant qu'agents de lutte contre le diabete et contre l'obesite, et procede associe
US20030125304A1 (en) *	2001-11-09	2003-07-03	Hans-Ulrich Demuth	Substituted amino ketone compounds
US20030089935A1 (en) *	2001-11-13	2003-05-15	Macronix International Co., Ltd.	Non-volatile semiconductor memory device with multi-layer gate insulating structure
MXPA04004956A (es) *	2001-11-26	2004-08-11	Schering Corp	Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central.
EP1790353A1 (fr) *	2001-12-29	2007-05-30	Novo Nordisk A/S	Utilisation combinée d'un composé GLP-1 et d'un modulateur de complications diabétiques tardives
DE60323823D1 (de) *	2002-01-11	2008-11-13	Novo Nordisk As	Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
US7101898B2 (en) *	2002-02-01	2006-09-05	Novo Nordisk A/S	Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
JP4216197B2 (ja) *	2002-02-13	2009-01-28	エフ．ホフマン−ラロシュアーゲー	新規ピリジン及びキノリン誘導体
PL371678A1 (en) *	2002-02-13	2005-06-27	F.Hoffmann-La Roche Ag	Novel pyridin- and pyrimidin-derivatives
ES2246481T3 (es) *	2002-02-27	2006-02-16	Pfizer Products Inc.	Inhibidores de la acc.
US20030232761A1 (en) *	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
CN1633420A (zh) *	2002-04-08	2005-06-29	托伦脱药品有限公司	噻唑烷－4－腈和类似物以及它们作为二肽基－肽酶抑制剂的用途
TW200307667A (en) *	2002-05-06	2003-12-16	Bristol Myers Squibb Co	Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7057046B2 (en) *	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
AU2003233010A1 (en) *	2002-06-04	2003-12-19	Pfizer Products Inc.	Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
US20040009972A1 (en) *	2002-06-17	2004-01-15	Ding Charles Z.	Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
SE0201976D0 (sv) *	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
US6998502B1 (en) *	2002-09-05	2006-02-14	Sabinsa Corporation	Convenient process of manufacture for difluoromethylornithine and related compounds
DE602004026289D1 (de) *	2003-05-05	2010-05-12	Probiodrug Ag	Glutaminylcyclase-hemmer
KR20060041309A (ko) *	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
BRPI0507485A (pt) *	2004-02-05	2007-07-10	Probiodrug Ag	inibidores novos de glutaminil ciclase
KR101071390B1 (ko) *	2004-03-15	2011-10-07	다케다 야쿠힌 고교 가부시키가이샤	디펩티딜 펩티다제 억제제
CA2590912A1 (fr) *	2004-12-24	2006-06-29	Dainippon Sumitomo Pharma Co., Ltd.	Derives bicycliques de pyrrole
PT1931350E (pt) *	2005-09-14	2014-02-12	Takeda Pharmaceutical	Administração de inibidores de dipeptidil peptidase
PE20070622A1 (es) *	2005-09-14	2007-08-22	Takeda Pharmaceutical	Administracion de inhibidores de dipeptidil peptidasa
MY147393A (en) *	2005-09-14	2012-11-30	Takeda Pharmaceutical	Administration of dipeptidyl peptidase inhibitors

2007
- 2007-09-11 AT AT07842260T patent/ATE522216T1/de active
- 2007-09-11 PL PL07842260T patent/PL2073810T3/pl unknown
- 2007-09-11 CA CA2663279A patent/CA2663279C/fr active Active
- 2007-09-11 AR ARP070104030A patent/AR062760A1/es not_active Application Discontinuation
- 2007-09-11 WO PCT/US2007/078177 patent/WO2008033851A2/fr not_active Ceased
- 2007-09-11 MY MYPI20090970A patent/MY145447A/en unknown
- 2007-09-11 CN CN2013101421944A patent/CN103211819A/zh active Pending
- 2007-09-11 ES ES07842260T patent/ES2370873T3/es active Active
- 2007-09-11 RS RS20110472A patent/RS51965B/sr unknown
- 2007-09-11 EA EA200970273A patent/EA017799B1/ru unknown
- 2007-09-11 EP EP07842260A patent/EP2073810B1/fr active Active
- 2007-09-11 NZ NZ575521A patent/NZ575521A/en unknown
- 2007-09-11 DK DK07842260.7T patent/DK2073810T3/da active
- 2007-09-11 BR BRPI0716971-0A2A patent/BRPI0716971A2/pt not_active Application Discontinuation
- 2007-09-11 MX MX2009002772A patent/MX2009002772A/es active IP Right Grant
- 2007-09-11 PT PT07842260T patent/PT2073810E/pt unknown
- 2007-09-11 GE GEAP200711217A patent/GEP20125701B/en unknown
- 2007-09-11 JP JP2009528434A patent/JP5791228B2/ja active Active
- 2007-09-11 CN CN200780039574A patent/CN101616673A/zh active Pending
- 2007-09-11 PE PE2007001217A patent/PE20081150A1/es not_active Application Discontinuation
- 2007-09-11 KR KR1020097007057A patent/KR20090088854A/ko not_active Ceased
- 2007-09-11 SI SI200730772T patent/SI2073810T1/sl unknown
- 2007-09-11 HR HR20110800T patent/HRP20110800T1/hr unknown
- 2007-09-11 AU AU2007296556A patent/AU2007296556B2/en active Active
- 2007-09-11 KR KR1020157004543A patent/KR20150032590A/ko not_active Ceased
- 2007-09-11 KR KR1020177032684A patent/KR20170127074A/ko not_active Ceased
- 2007-09-11 KR KR1020197013794A patent/KR102062824B1/ko active Active
- 2007-09-12 JO JO2007385A patent/JO2755B1/en active
- 2007-09-12 CL CL200702649A patent/CL2007002649A1/es unknown
- 2007-09-12 TW TW096134051A patent/TWI434838B/zh active
2008
- 2008-03-12 US US12/046,997 patent/US20080287476A1/en not_active Abandoned
2009
- 2009-03-09 IL IL197502A patent/IL197502A/en active IP Right Grant
- 2009-03-10 TN TN2009000079A patent/TN2009000079A1/fr unknown
- 2009-03-17 NO NO20091133A patent/NO342004B1/no unknown
- 2009-03-30 MA MA31740A patent/MA30725B1/fr unknown
- 2009-03-31 CO CO09032924A patent/CO6160321A2/es unknown
- 2009-04-09 EC EC2009009250A patent/ECSP099250A/es unknown
2010
- 2010-12-10 US US12/965,448 patent/US20110077402A1/en not_active Abandoned
2011
- 2011-11-22 CY CY20111101129T patent/CY1112292T1/el unknown
2015
- 2015-02-05 JP JP2015020882A patent/JP2015129143A/ja active Pending
2017
- 2017-10-31 AR ARP170103019A patent/AR110010A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
TWI434838B (zh)	2014-04-21
JP2015129143A (ja)	2015-07-16
PE20081150A1 (es)	2008-10-03
EP2073810B1 (fr)	2011-08-31
HK1131057A1 (en)	2010-01-15
US20080287476A1 (en)	2008-11-20
WO2008033851A2 (fr)	2008-03-20
AU2007296556A1 (en)	2008-03-20
CO6160321A2 (es)	2010-05-20
GEP20125701B (en)	2012-12-10
KR20190054186A (ko)	2019-05-21
CN101616673A (zh)	2009-12-30
HRP20110800T1 (hr)	2011-12-31
US20110077402A1 (en)	2011-03-31
WO2008033851A3 (fr)	2008-08-28
MA30725B1 (fr)	2009-09-01
CY1112292T1 (el)	2015-12-09
IL197502A0 (en)	2009-12-24
KR102062824B1 (ko)	2020-01-07
AR062760A1 (es)	2008-12-03
NO20091133L (no)	2009-05-14
EP2073810A2 (fr)	2009-07-01
IL197502A (en)	2014-06-30
NO342004B1 (no)	2018-03-12
KR20150032590A (ko)	2015-03-26
JO2755B1 (en)	2014-03-15
TW200827344A (en)	2008-07-01
ECSP099250A (es)	2009-06-30
KR20090088854A (ko)	2009-08-20
AR110010A2 (es)	2019-02-13
RS51965B (sr)	2012-02-29
ATE522216T1 (de)	2011-09-15
BRPI0716971A2 (pt)	2013-10-15
CN103211819A (zh)	2013-07-24
EA200970273A1 (ru)	2009-08-28
JP2010503695A (ja)	2010-02-04
EA017799B1 (ru)	2013-03-29
NZ575521A (en)	2012-03-30
DK2073810T3 (da)	2011-10-31
CA2663279A1 (fr)	2008-03-20
PL2073810T3 (pl)	2012-01-31
KR20170127074A (ko)	2017-11-20
JP5791228B2 (ja)	2015-10-07
ES2370873T3 (es)	2011-12-23
CL2007002649A1 (es)	2008-04-11
PT2073810E (pt)	2011-09-30
SI2073810T1 (sl)	2011-12-30
AU2007296556B2 (en)	2013-09-19
CA2663279C (fr)	2016-05-17
MY145447A (en)	2012-02-15
MX2009002772A (es)	2009-05-28

Publication	Publication Date	Title
TN2009000079A1 (en)	2010-08-19	Use of 2-6 (3-amino-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile
TW200744602A (en)	2007-12-16	Administration of dipeptidyl peptidase inhibitors
MY149157A (en)	2013-07-15	Weekly administration of dipeptidyl peptidase inhibitors
IL199151A (en)	2017-01-31	Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
MY159522A (en)	2017-01-13	Administration of dipeptidyl peptidase inhibitors
MX2010004576A (es)	2010-05-17	Derivados de pirimidina novedosos.
IN2012DN02577A (fr)	2015-08-28
TN2010000236A1 (en)	2011-11-11	Fused pyridine pyrimidine and triazine compounds as cell cycle inhibitors
IL198866A0 (en)	2010-02-17	Polymorphs of succinate salt of 2 - [6 - (3 - amino-piperidin - 1 - yl) - 3 - methyl - 2,4 - dioxo - 3, 4 -dihydro - 2h - pyrimidin - 1 - ylmethyl] - 4 - fluor - benzonitrile and methods of use thereof
IL192763A (en)	2013-04-30	History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
MX2009004807A (es)	2009-06-15	Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
WO2010077740A3 (fr)	2010-09-23	Nouveaux composés antiviraux, compositions et procédés d'utilisation
WO2008031556A3 (fr)	2008-06-12	Nouveaux dérivés de la 2-amino-pyrimidine, procédés pour les préparer, compositions pharmaceutiques les contenant
AU2009276339A8 (en)	2011-03-03	Pyrimidine compounds, compositions and methods of use
MX2008013582A (es)	2009-01-19	Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
MX2009009117A (es)	2009-09-03	Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
WO2008027600A3 (fr)	2008-04-24	Compositions d'imatinib
AU2007329728A1 (en)	2008-06-12	3-(dihydro-1H-pyrazolo (4,3-d) pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
EP2184277A4 (fr)	2012-01-04	Dérivés d'arylpyrimidine, procédés de préparation et utilisations pharmaceutiques de ces dérivés
UA99112C2 (en)	2012-07-25	Use of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydr0-2h-pyrimidin-1-ylmethyl]-4-fluorobenzonitrile
WO2007043094A3 (fr)	2007-07-05	Derives de 6-vinyl pyrimidine et de pyrimidinone et leur utilisation
JO3254B1 (ar)	2018-09-16	مثبطات ببتيداز ثنائي ببتيديل لمعالجة مرض السكر
WO2010077734A3 (fr)	2010-09-23	Nouveaux composés antiviraux, compositions et procédés d'utilisation
HK1137024A (en)	2010-07-16	Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors
HK1134785A (en)	2010-05-14	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor